MAIA Biotechnology (NYSEA: MAIA) updated preliminary survival data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial, evaluating THIO in sequential combination with cemiplimab in patients with advanced non-small cell lung cancer (NSCLC).
The first two patients enrolled in the study continue to be alive, approximately 12.2 and 11.5 months, respectively, from the start of treatment. Both patients have advanced Stage IV metastatic disease and failed two prior lines of therapy, including one line with an immune checkpoint inhibitor (CPI), and platinum-based chemotherapy.
Following the conclusion of study treatment, they have remained free of disease progression for 10.2 and 8.5 months, respectively, without requiring any additional therapy. No new safety analysis was conducted.
“These results align with our hypothesis that THIO, followed by an immune CPI, can re-sensitize tumors to the CPI and stimulate a potent and long-lasting anti-cancer immune response,” Vlad Vitoc, MAIA’s CEO, said in a statement.
He said patients with advanced NSCLC who failed two or more therapy regimens in real-world scenarios have an expected survival of only three-to-four months. With therapy, third-line patients generally survive about six months; without therapy, survival is only weeks.
